FOR IMMEDIATE RELEASE March 27, 2009 AMA REQUESTS JOURNAL OVERSIGHT COMMITTEE REVIEW Statement attributable to: Joseph M. Heyman, M.D. AMA Board Chair "The American Medical Association is owner and publisher of the Journal of the American Medical Association (JAMA) and its specialty Archives journals. While we are…
AHRP has sent a letter of complaint to the American Medical Association and the JAMA Oversight Committee calling for a public apology to Dr. Jonathan Leo by the AMA, a thorough investigation, the immediate suspension of the two editors involved, and a commitment to reviewing, clarifying and publishing JAMA’s editorial policies to protect against future violations of standards for professional conduct
The most shocking disclosure is that Dr. Biederman’s study testing powerful antipsychotics in PRESCHOOL CHILDREN "was beset by breaches of research protocol,"
The most shocking disclosure: a Biederman study testing the use of powerful antipsychotics in PRESCHOOL CHILDREN "was beset by breaches of research protocol."
A series of slides, all prepared by Dr. Biederman–according to his sworn testimony–are revealing as they raise serious doubts about the scientific and ethical integrity of his oeuvre.
The disconnect provides further evidence of how the prescription drug industry can shape, revise or even conceal negative research findings that affect the way doctors prescribe.
Study 15 was pivotal to AstraZeneca gaining FDA approval to market Seroquel. The burial of negative data suggests that the approval process was tainted and the drug's license should be recalled.
JAMA Editor Ignites Firestorm By Calling Critic a ‘Nobody and a Nothing’_WSJ
But, funding for research aimed at answering a scientific question will still not have to be disclosed…
"Radical restructuring, not merger mania, is the need of our time." Dr. William Haseltine
Why is FDA Silent? Seroquel Victim Asked Judge to Unseal Documents for FDA Advisory
Dr. Margaret "Peggy" Hamburg, a former health commissioner in New York City, is the leading candidate to become FDA commissioner, the agency's top job, while Baltimore health chief Joshua Sharfstein is in line to become a deputy commissioner
